30 closest matches · ranked by relevance
Antiphospholipid Syndrome
Primary: Number of Participants Experiencing Serious and Non Serious Adverse Events — 19 Participants
Antiphospholipid Syndrome
Primary: Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients — 31.2; 12.2; 0.4; 2.7 pg/mL
Recurrent Abortion
Primary: Live Birth Rate = (Number of Live Births / Total Number of Pregnancies) — 24; 20 Percentage of pregnancies
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants
Systemic Lupus Erythematosus
Primary: Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 3 — -0.32; 0.09 unitless
Pre-Eclampsia · Pre-Term · Intrauterine Growth Restriction
Primary: Blood Pressure (mmHg) — 122; 116 mmHg
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Type2 Diabetes
Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
Amyotrophic Lateral Sclerosis
Primary: Number of Participants Who Had Any Serious Adverse Events or Any Adverse Events With Severity Higher Than "Moderate". — 0; 0 Participants
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants
Congenital Heart Block · Neonatal Lupus · Autoantibody-Associated Heart Block
Primary: Recurrence of Advanced Heart Block — 5 Participants
Covid19
Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…
Venous Thrombosis · Pulmonary Embolism
Primary: Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population — 2.71…
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
Lupus Erythematosus, Systemic
Primary: Change in Mean-Mean Common Carotid IMT (CIMT) — 0.0010; 0.0024 mm
Healthy
Primary: AUC — 4.78; 15.00; 5.41; 16.34 uM hr/L
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
ALPS · Hypersplenism · Lymphadenopathy
Primary: Number of Participants With Response — 0 participants
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
Cardiovascular Diseases · Metabolic Syndrome X · Atherosclerosis
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL
Metabolic Syndrome X · Overweight · Hypertension
Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279
Recurrent Miscarriage · Spontaneous Abortion · Mannose-Binding Lectin Deficiency
Primary: Plasma MBL Level (ug/ml) — 717; 1717 ug/l — p=<0.001